Optune Pax: A Novel Wearable Tumor Treating Fields Device for Locally Advanced Pancreatic Cancer

On February 12, 2026, the U.S. Food and Drug Administration (FDA) approved Optune Pax (Novocure), a first-of-its-kind portable, non-invasive device, for the treatment of adult patients with locally advanced pancreatic cancer when used concomitantly with gemcitabine and nab-paclitaxel (gem/nab-pac). This marks the first new FDA-approved therapy in nearly 30 years for this aggressive disease, which affects patients whose tumors remain unresectable but have not metastasized distantly. Optune Pax delivers Tumor Treating Fields (TTFields) therapy at 150 kHz directly to the abdomen, offering a biophysical approach that complements standard chemotherapy without adding significant systemic toxicity.

The Optune Pax device components.

Mechanism of Action: Disrupting Cancer Cell Division with Electric Fields

TTFields are low-intensity, alternating electric fields that target the unique electrical properties of rapidly dividing cancer cells. Delivered continuously via four adhesive transducer arrays placed on the skin of the abdomen, the fields exert physical forces on charged intracellular components—such as microtubules, septins, and organelles—during mitosis.

These forces disrupt key processes:

• Mitotic spindle formation and chromosome alignment

• Cytokinesis (cell cleavage)

• Membrane permeability and other cellular functions

The result is mitotic arrest, abnormal chromosome segregation, and ultimately apoptosis or other forms of cell death. Because TTFields are tuned to the specific frequency (150 kHz for pancreatic adenocarcinoma) and primarily affect cells with high division rates, they spare most healthy, non-dividing tissues.

Diagram illustrating TTFields mechanisms: interference with mitosis (proliferation) leading to cell death pathways, without broadly affecting healthy cells.

This non-pharmacologic, targeted approach addresses a key limitation in pancreatic cancer treatment—poor drug penetration into dense tumors—while synergizing with gemcitabine and nab-paclitaxel.

How Optune Pax Is Used: Practical, Home-Based Therapy

Optune Pax consists of a portable electric field generator (worn in a specially designed bag), rechargeable batteries, a power supply, connection cables, and disposable transducer arrays. The device is preset by the manufacturer; patients or caregivers receive training from a Novocure-trained specialist on setup, array placement, and maintenance.

Key usage guidelines:

• Array placement: Four arrays (two pairs with black/white connectors) are positioned on the front and back of the abdomen per a physician-provided layout. Arrays are changed every 3–4 days; placement is shifted slightly (~2 cm) each time to minimize skin irritation. Skin preparation involves shaving (electric razor only), washing with mild soap, and applying prescribed moisturizers or steroid creams.

• Wear time: Minimum average of 12–18 hours per day (longer use correlates with better outcomes). Patients can continue daily activities, sleep, or travel while wearing the device. Short breaks for showering or exercise are allowed but should be minimized.

• Power options: Battery-powered for mobility or plugged into a wall outlet for extended use.

• Compliance support: The device includes alarms for low battery, poor connection, or overheating. Novocure provides ongoing support, including array supply and troubleshooting.

A patient using the Optune Pax, a portable wearable system with transducer arrays on the abdomen and a generator carried in a bag for daily activities.

Patients must avoid wetting the device, using non-approved parts, or wearing it near electrical implants (contraindicated). It is not for use during pregnancy.

Clinical Effectiveness: Data from the Pivotal PANOVA-3 Trial

Approval was based on the international, randomized, open-label Phase 3 PANOVA-3 trial (NCT03377491), which enrolled 571 patients with newly diagnosed, unresectable locally advanced pancreatic adenocarcinoma. Patients received gem/nab-pac with or without Optune Pax (TTFields 150 kHz) until abdominal progression.

Key efficacy results (intent-to-treat population):

• Median overall survival (primary endpoint): 16.2 months (95% CI 15.0–18.0) with Optune Pax + gem/nab-pac vs. 14.2 months (95% CI 12.8–15.4) with gem/nab-pac alone (HR 0.82; 95% CI 0.68–0.99; p=0.039). In the modified per-protocol population (patients with adequate exposure), the benefit increased to 18.3 vs. 15.1 months (HR 0.77; p=0.023).

• 1-year survival rate: 68.1% vs. 60.2%.

• Time to pain progression (key secondary endpoint): 15.2 months vs. 9.1 months—a clinically meaningful 6.1-month delay.

• Quality of life: Longer deterioration-free survival in global health status, pain, pancreatic pain, and digestive symptoms (EORTC QLQ-C30 + PAN26). No detriment to emotional function or fatigue.

No significant differences were observed in progression-free survival or objective response rate, but the survival and symptom benefits represent meaningful progress in a disease with historically limited options.

Safety Profile and Side Effects

Optune Pax was well tolerated and did not increase chemotherapy-related systemic toxicities. Serious adverse events were comparable between arms, with no device-related deaths or new safety signals.

Most common device-related adverse events (PANOVA-3):

• Skin reactions under the arrays (inflammation, rash, itching, redness): 76.3% (mostly Grade 1–2; 7.7% Grade ≥3). Manageable with proper skin care, topical steroids, and array repositioning.

• Fatigue: ~5%.

• Other rare events: Local warmth/tingling, allergic reaction to adhesive/gel, or array overheating (preventable with proper use).

Systemic side effects mirrored those of gem/nab-pac alone (e.g., neutropenia, nausea, fatigue, neuropathy). Skin irritation is the primary manageable risk and typically improves with proactive care.

Contraindications include active electrical implants in the torso, known sensitivity to conductive gels, and pregnancy.

Clinical Considerations and Patient Selection

Optune Pax is indicated for adults with locally advanced (unresectable but non-metastatic) pancreatic adenocarcinoma as first-line therapy alongside gem/nab-pac. Ideal candidates are those with ECOG performance status 0–2 who can comply with daily use and skin care. Multidisciplinary teams (oncologists, nurses, device specialists) play a key role in training and monitoring.

Insurance coverage (including Medicare) is generally available post-approval, though prior authorization may be required. Patient support programs through Novocure and organizations like the Pancreatic Cancer Action Network (PanCAN) provide education, financial assistance navigation, and peer support.

Looking Ahead

Optune Pax introduces a fundamentally different, home-based treatment modality that extends survival, delays pain, and preserves quality of life with a favorable safety profile. As real-world experience grows and additional studies (e.g., combinations with immunotherapy) mature, this technology may further transform care for one of oncology’s most challenging diseases.

For full prescribing information, patient manuals, or to locate trained centers, visit the Novocure or FDA websites. Clinicians and patients are encouraged to discuss this option early in the treatment planning process.